Paclitaxel and immune system

Chemotherapy remains the mainstay of treatment for both early stage as well as metastatic tumors. Paclitaxel (PTX), a novel anticancer drug, is a prominent taxane which is active against a broad range of tumors that are generally considered to be refractory to conventional chemotherapy, with benefit...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutical sciences 2009-11, Vol.38 (4), p.283-290
Main Authors: JAVEED, Aqeel, ASHRAF, Muhammad, RIAZ, Amjad, GHAFOOR, Aamir, AFZAL, Sheryar, MUHAMMAD MAHMOOD MUKHTAR
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Autoimmune Diseases - drug therapy
Autoimmune Diseases - immunology
Autoimmune Diseases - pathology
Biological and medical sciences
General pharmacology
Humans
Immunity, Cellular - drug effects
Immunity, Cellular - immunology
Immunologic Factors - pharmacology
Immunologic Factors - therapeutic use
Medical sciences
Paclitaxel - pharmacology
Paclitaxel - therapeutic use
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
T-Lymphocytes, Regulatory - drug effects
T-Lymphocytes, Regulatory - immunology
T-Lymphocytes, Regulatory - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy remains the mainstay of treatment for both early stage as well as metastatic tumors. Paclitaxel (PTX), a novel anticancer drug, is a prominent taxane which is active against a broad range of tumors that are generally considered to be refractory to conventional chemotherapy, with benefits gained in terms of overall survival and disease-free survival. PTX is initially characterized as a mitotic inhibitor, and its anti-neoplastic effect is derived from binding to tubulin and excessive microtubule stabilization. Interestingly, drugs traditionally used for tumor cytoreduction, can exert both positive and negative effects on the host's immune system. PTX also exerts effects on the immune system and displays immunomodulatory traits. For example, PTX is immunostimulatory against tumors and also regulates lymphocyte activation suggesting that apart from promoting inhibition in cell division, it also has some other features and mechanisms which need to be taken into account. The present article reviews the clinical and experimental findings with regard to the effects of PTX on the immune cells including macrophages, dendritic cells (DCs), natural killer (NK) cells, and T and B lymphocytes together with its clinical applications in autoimmune disorders and organ transplantation which reflect greater therapeutic application of PTX beyond tumor chemotherapy.
ISSN:0928-0987
1879-0720
DOI:10.1016/j.ejps.2009.08.009